HARP - Shares of Harpoon Therapeutics Inc. (HARP) Have Risen Above Previous 52-Week High
Harpoon Therapeutics Inc. (NASDAQ:HARP) traded at a new 52-week high today of $25.05. Approximately 10.9 million shares have changed hands today, as compared to an average 30-day volume of 503,000 shares.
Over the past year, Harpoon Therapeutics Inc. has traded in a range of $3.30 to $24.20 and is now at $5.06.
Harpoon Therapeutics Inc. (NASDAQ:HARP) has potential upside of 0.7% based on a current price of $5.06 and analysts' consensus price target of $5.10.
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer